The disclosure relates generally to methods for the preparation of a family of natural compounds, the syrbactins and their analogs.

The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.

The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II):

##STR00001## including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R.sup.1, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, R.sup.4, R.sup.5, R.sup.6a, R.sup.6b, R.sup.6c, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

The present application relates to new HtrA inhibitors and use thereof. Additionally, the present application also relates to new peptides for inhibiting CagA and use thereof.

The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.

The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.

Provided are macrocyclic compounds and compounds with two or more macrocyclic groups, iron coordinated macrocyclic compounds, and iron coordinated compounds with two or more macrocyclic groups. The iron is high-spin iron(III). The iron coordinated compounds may exhibit a negative redox potential (e.g., relative to a normal hydrogen electrode at a biologically relevant pH, for example, a pH of 6.5-7.5). The compounds can be used as MRI contrast agents.

The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.

The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.